


## Curriculum vitae

<b>Dr. med. Livius Penter</b> Forum 4, Raum 1.0523 Augustenburger Platz 1 13353 Berlin Germany	+49 (0)30 450 553 615 <a href="mailto:Livius.Penter@charite.de">Livius.Penter@charite.de</a>  <a href="https://orcid.org/0000-0002-9060-0207">0000-0002-9060-0207</a>	Born October 02, 1987 in Dresden, Germany Married, 1 child <a href="http://www.penterlab.org">www.penterlab.org</a>
--	--	--



## Research

Since 10/2023	<b>Charité – Universitätsmedizin Berlin, Germany</b> Max-Eder Research Group leader <i>Cancer and immune cell co-evolution</i>
10/2019 – 09/2023	<b>Dana-Farber Cancer Institute, USA</b> Postdoctoral research fellow (Wu Lab) <i>CTLA-4 blockade for relapsed myeloid malignancies after transplantation</i>
06/2015 – 09/2019	<b>Charité – Universitätsmedizin Berlin, Germany</b> Postdoctoral research fellow (Hansmann Lab) <i>Immunologic biomarkers and therapeutic targets in rectal cancer</i>
08/2009 – 05/2015	<b>Laboratory of Pediatric Molecular Biology Berlin, Germany</b> Medical thesis (Prof. Hagemeier) <i>Development of a lentiviral shRNA screen in SH-EP neuroblastoma cells</i>
06 – 08/2013	<b>Research Institute of Molecular Pathology Vienna, Austria</b> Vienna Biocenter Summer School (Zuber Lab)
09/2005 – 06/2007	<b>Max Planck Institute of Molecular Cell Biology Dresden, Germany</b> School project: <i>Phylogenetic analysis of proteins using bioinformatics tools</i>

## Education

Since 10/2023	<b>Berlin Institute of Health</b> Digital Clinician Scientist
07/2016 – 07/2018	<b>Berlin Institute of Health</b> Junior Clinician Scientist
01/2015 – 09/2019	<b>Charité – Universitätsmedizin Berlin</b> Internal Medicine and Hematology/Oncology
05/2015	Medical thesis with grade 1.0 (magna cum laude)
11/2014	Medical state examination with grade 1.33 (1.0=best, 5.0=bottom)
06/2007	<b>Martin-Andersen-Nexö-Gymnasium Dresden, Germany</b> High school diploma with grade 1.0 (1.0=best, 6.0=bottom) <i>Prizes in informatics competitions and work as administrator of computer pool</i>

## International experience

	<b>McGill University Montreal, Canada</b>
02 – 04/2014	Clinical electives in cardiology and nephrology
	<b>Université Diderot Paris VII, France</b>
09/2013 – 02/2014	Clinical electives in general surgery and medical oncology
	<b>Université Pierre et Marie Curie Paris VI, France</b>
08/2011 – 06/2012	ERASMUS exchange
	<b>Bangalore Baptist Hospital, India</b>
02 – 03/2010	Clinical elective in general surgery
	<b>Morrin High School, Alberta, Canada</b>
09/2004 – 06/2005	High school diploma

## Scholarships, awards and grants

11/2023	Else Kröner-Fresenius-Stiftung – Research Grant
Since 10/2023	Berlin Institute of Health – Digital Clinician Scientist Grant
01 – 06/2023	EHA-EMBL/EBI Computational Biology Training in Hematology (CBTH)
07/2022	ASH Scholar Award
12/2020 and 12/2021	ASH Achievement Award
10/2019 – 03/2022	German Research Foundation (DFG) – Research Fellowship
07/2016 – 06/2018	Berlin Institute of Health – Junior Clinician Scientist Grant
09/2013 – 04/2014	German Academic Exchange Service (DAAD) – Exchange Scholarship
08/2013	Vienna Biocenter – VWR Summer School Prize
05/2010 – 11/2014	German Academic Scholarship Foundation – University Scholarship

## Languages spoken

German	native
English	near-native (C2)
French	proficient (C1)
Romanian	proficient (C1)

## Selected Publications

### Charité – Universitätsmedizin Berlin (since 2023)

*Integrative genotyping of cancer and immune phenotypes by long-read sequencing*

Penter L\*, Borji M\*, Nagler A\*, Lyu H, Lu W, Cieri N, Maurer K, Oliveira G, Al'Khafaji AM, Garimella KV, Li S, Neuberg DS, Ritz J, Soiffer RJ, Garcia JS, Livak KJ, Wu CJ

**Nature Communications.** 2024 Jan 2;15(1):32. **IF 16.6**

### Dana-Farber Cancer Institute (2019 – 2023)

*Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease*

Penter L, Liu Y, Wolff JO, Yang L, Taing L, Jhaveri A, Southard J, Patel M, Cullen NM, Pfaff KL, Cieri N, Oliveira G, Kim-Schulze S, Ranasinghe S, Leonard R, Robertson T, Morgan EA, Chen HX, Song MH, Thurin M, Li S, Rodig SJ, Cibulskis C, Gabriel S, Bachireddy P, Ritz J, Streicher H, Neuberg DS, Hodi FS, Davids MS, Gnjjatic S, Livak KJ, Altreuter J, Michor C, Soiffer RJ, Garcia JS, Wu CJ

**Blood.** 2023 Apr 13;141(15):1817-1830. **IF 20.3**

*Mitochondrial DNA mutations as natural barcodes for lineage tracing of murine tumor models*

Penter L\*, ten Hacken E\*, Southard J, Lareau CA, Ludwig LS, Li S, Neuberg DS, Livak KJ, Wu CJ

**Cancer Research.** 2023 Mar 2;83(5):667-672. **IF 11.2**

*AML relapse after a TIGIT race*

Penter L, Wu CJ

**Blood.** 2022 Sep 15;140(11):1189-1191. **IF 20.3**

*Natural Barcodes for Longitudinal Single Cell Tracking of Leukemic and Immune Cell Dynamics*

Penter L, Gohil SH, Wu CJ

**Frontiers in Immunology.** 2022 12:788891. **IF 8.8**

*Coevolving JAK2V617F<sup>+</sup> relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case*

Penter L, Gohil SH, Huang T, Thrash EM, Schmidt D, Li S, Severgnini M, Neuberg DS, Hodi FS, Livak KJ, Zeiser R, Bachireddy P, Wu CJ

**Blood Advances.** 2021 5(22):4701-4709. **IF 7.6**

*Longitudinal single-cell dynamics of chromatin accessibility and mitochondrial mutations in chronic lymphocytic leukemia mirror disease history*

Penter L\*, Gohil SH\*, Lareau C, Ludwig LS, Parry EM, Huang T, Li S, Zhang W, Livitz D, Leshchiner I, Parida L, Getz G, Rassenti LZ, Kipps TJ, Brown JR, Davids MS, Neuberg DS, Livak KJ, Sankaran VG, Wu CJ.

**Cancer Discovery.** 10.1158/2159-8290.CD-21-0276. 2021 **IF 38.3**

*Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation*

Penter L, Zhang Y, Savell A, Huang T, Cieri N, Thrash EM, Kim-Schulze S, Jhaveri A, Fu J, Ranasinghe S, Li S, Zhang W, Hathaway ES, Nazzaro M, Kim HT, Chen H, Thurin M, Rodig SJ, Severgnini M, Cibulskis C, Gabriel S, Livak KJ, Cutler C, Antin JH, Nikiforow S, Koreth J, Ho VT, Armand P, Ritz J, Streicher H, Neuberg D, Hodi FS, Gnjjatic S, Soiffer RJ, Liu XS, Davids MS, Bachireddy P, Wu CJ.

**Blood.** 2021 137 (23), 3212-3217. **IF 25.5**

*Personal tumor antigens in blood malignancies: genomics-directed identification and targeting*

Penter L, Wu CJ

**JCI.** 2020 130 (4), 1595-1607. **IF 14.8**

### Charité – Universitätsmedizin Berlin (2015 – 2019)

*Localization-associated immune phenotypes of clonally expanded tumor-infiltrating T cells and distribution of their target antigens in rectal cancer*

Penter L, Dietze K, Ritter J, Lammoglia-Cobo MF, Garmshausen J, Aigner F, Bullinger L, Hackstein H, Wienzek-Lischka S, Blankenstein T, Hummel M, Dornmair K, Hansmann L.

**Onc Immunology.** 2019 8 (6), e1586409. **IF 5.9**

*FACS single cell index sorting is highly reliable and determines immune phenotypes of clonally expanded T cells*

Penter L, Dietze K, Bullinger L, Westermann J, Rahn HP, Hansmann L.

**Eur J Immunol.** 2018 Jul;48(7):1248-1250. **IF 4.7**

*A rapid screening system evaluates novel inhibitors of DNA methylation and suggests F-box proteins as potential therapeutic targets for high-risk neuroblastoma*

Penter L, Maier B, Frede U, Hackner B, Carell T, Hagemeyer C, Truss M.

**Target Oncol.** 2015 Dec;10(4):523-33. **IF 2.9**